argenx

👥 501-1000💰 $1.1B Post-IPO Equity on 2023-07-19BiotechnologyTherapeuticsClinical Trials
Website LinkedIn Email Phone # Twitter

argenx is a global immunology company dedicated to enhancing the quality of life for individuals afflicted with severe autoimmune diseases and cancer.